Stay updated with breaking news from Prostatype Genomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish National...
Prostatype Genomics AB announces today the final outcome of the share issue with preferential rights for the Company's shareholders whose subscription period ended on 11 May 2023. The subscription... | May 16, 2023
/PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics....
With effect from April 27, 2023, the subscription rights in Prostatype Genomics AB will be traded on First North Growth Market. Trading will continue up until and including May 08, 2023. Instrument:
Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Steven's task will be to establish and launch Prostatype®, the company's genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately.